Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 10;99(28):e20966.
doi: 10.1097/MD.0000000000020966.

Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis: A retrospective cohort study

Affiliations

Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis: A retrospective cohort study

Yida Xing et al. Medicine (Baltimore). .

Abstract

To investigate the effectiveness of dual filtration plasmapheresis (DFPP), a novel blood purification treatment, as a rapid and sustained disease-modifying therapy for active refractory rheumatoid arthritis (RA).A retrospective cohort study had been conducted. One hundred fifty three patients aged 18 years or older with active refractory RA were treated with DFPP combined with infliximab (IFX), IFX, or glucocorticoid (GC), all the above treatments were combined with methotrexate (MTX).Baseline characteristic of the 153 patients (DFPP: n = 53; IFX: n = 51; GC: n = 49) were similar across groups. The remission rate of CDAI (SDAI) in the DFPP treatment group was significantly higher than that of the IFX and GC group after 3 months of treatment. The remission rate of DFPP treatment group was above 50%, while in IFX and GC group, the rate of CDAI (SDAI) remission was 41.2% (37.3%) and 22.4% (14.2%) after 3 months of treatment.A combination of DFPP and biological agents can quickly induce remission or low disease activity of active refractory RA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The REM and LDA rates of DFPP treatment were higher than those of the other 2 groups at M1, M3, M6 (A). Patients were grouped according to age, gender, and course of disease. The younger the patients, the higher the rates of REM and LAD of 3 different treatments (B). The shorter the course of the disease, the higher the rates of REM and LAD of 3 different treatments (C). The REM and LAD rates of Male patients were higher than those of female patients of 3 different treatments (D). DFPP = dual filtration plasmapheresis, GC = glucocorticoid, IFX = infliximab, LDA = low disease activity, REM = remission.

Similar articles

References

    1. Johnsson PM, Eberhardt K. Hand deformities are important signs of disease severity in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1398–401. - PubMed
    1. Boissier MC, Semerano L, Challah S, et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012;39:222–8. - PubMed
    1. Zhanguo L. Facing the challenge of low recognition and high status in rheumatoid arthritis. Natl Med J China 2009;89:1873–5. - PubMed
    1. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3–15. - PMC - PubMed
    1. Mishima M, Agishi T, Kaneko I, et al. Performance evaluation of conventional and modified double filtration plasmapheresis (DFPP). Trans Am Soc Artif Intern Organs 1984;30:665–70. - PubMed